Scope 3 emissions - which include those from all suppliers in a company's supply chain - account for 96% of Novo's overall ...
Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has ...
Novo Nordisk (NVO) said on Wednesday that its emissions rose by nearly a quarter in 2024 and will continue to increase up to 2030 as production increases to meet demand for its obesity blockbuster ...
These ten new MoUs follow NUPCO’s recent agreements with global pharmaceutical leaders, including Novo Nordisk (Denmark) and ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
The firm then sold three of Catalent's plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion as part of the deal, to help the Danish drugmaker ramp up supplies of ...
Novo Nordisk has taken the bold step of buying ... but has been forced to introduce restrictions on starting doses to eke out supplies in the face of demand, which has become acute, with some ...
J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...